REGN5678

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Prostate CancerMetastatic Castration-Resistant Prostate Cancer, Mcrpc

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

1

Novantrone

Pfizer

Preclinical

52

Mekinist

Novartis

Preclinical

33

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

24

Duragesic

CCephalon

Preclinical

15

Triptorelin Pamoate

Ipsen

Preclinical

26

Ifex

BBaxter Healthcare Corporation

Preclinical

—7

Xylocaine

MMEDRx USA, Inc.

Preclinical

—8

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

—9

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—Show 14 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Recruiting·Regeneron·Phase 1/2·NCT05125016·370 enrolled

A Pilot Presurgical Trial of REGN5678 (Anti-PSMA X CD28) in Patients With High-Risk, Localized Prostate Cancer Followed by Radical Prostatectomy

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT06085664·42 enrolled

mCRPC1 trial

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06826768·60 enrolled

Metastatic Castration-resistant Prostate Cancer, mCRPC1 trial

A Phase 1/2 Study of REGN5678 (Anti-PSMAxCD28) With or Without Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Associated With PSMA Expression

Recruiting·Regeneron·Preclinical·NCT03972657·345 enrolled

Details

Drug Info

Related News